Physician's choice chemotherapy — Competitive Intelligence Brief

Physician's choice chemotherapy (Physician's choice chemotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy. Area: Oncology.

phase 3 Chemotherapy Oncology Small molecule

Target snapshot

Physician's choice chemotherapy (Physician's choice chemotherapy) — Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Physician's choice chemotherapy involves administering a selection of chemotherapy drugs tailored to the individual patient's needs.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Physician's choice chemotherapy TARGET	Physician's choice chemotherapy	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	phase 3	Chemotherapy
Eloxatin	Oxaliplatin	Yakult Honsha	marketed	Platinum-based chemotherapy agent	DNA	2002-01-01
Methotrexate + targeted therapy administration	Methotrexate + targeted therapy administration	University Hospital, Strasbourg, France	marketed	Combination chemotherapy with targeted agent	Dihydrofolate reductase (methotrexate component); targeted agent varies by protocol
ATRA+Chemo	ATRA+Chemo	Shanghai Jiao Tong University School of Medicine	marketed	Retinoid + chemotherapy combination	Retinoic acid receptor (RAR)
Adjuvant chemotherapy	Adjuvant chemotherapy	Institut de Cancérologie de Lorraine	marketed	Chemotherapy regimen (multi-agent or single-agent cytotoxic)
Consolidation Chemotherapy	Consolidation Chemotherapy	National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos	marketed	Combination chemotherapy regimen
Carboplatin or Cisplatin	Carboplatin or Cisplatin	Second Hospital of Shanxi Medical University	marketed	Platinum-based chemotherapy agent	DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy class)

1. University Hospital, Rouen · 2 drugs in this class
2. Sun Yat-sen University · 2 drugs in this class
3. Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
4. Beijing Biostar Pharmaceuticals Co., Ltd. · 1 drug in this class
5. Delcath Systems Inc. · 1 drug in this class
6. Ludwig-Maximilians - University of Munich · 1 drug in this class
7. Prof. Dr. med. Claus Rödel · 1 drug in this class
8. Prothena Biosciences Ltd. · 1 drug in this class
9. Seoul National University Hospital · 1 drug in this class
10. Shanghai Zhongshan Hospital · 1 drug in this class